This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.
No linked publications found in PubMed
Inclusion Criteria: * Histologically confirmed estrogen and/or progesterone receptor-positive breast cancer metastatic breast cancer * Clinically determined evaluable disease * Post-menopausal woman * Previous clinical benefit from prior anti-estrogen therapies and subsequent failure of at least 2 prior endocrine therapies. * May have had chemotherapy for adjuvant \&/or metastatic disease. * May have had radiation therapy but not to the only site of disease. * Ecog performance status \</= 2. * Life expectancy of \> 6 months Exclusion Criteria: * Chemotherapy or radiotherapy within 1 week of beginning treatment in the clinical trial * Brain metastasis * Prior history of or active thrombophlebitis, deep venous thrombosis or pulmonary embolus * Current vaginal bleeding * Hypercalcemia or hypocalcemia * History of or active hepatic adenoma * No other malignancies within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix